2012
Inherited and Acquired Thrombophilias
Paidas M. Inherited and Acquired Thrombophilias. 2012, 108-120. DOI: 10.1002/9781119963783.ch15.Peer-Reviewed Original ResearchAntiphospholipid antibody syndromePlacenta-mediated complicationsAntibody syndromeThrombophilic conditionsProthrombin G20210A gene mutationFactor V Leiden mutationBenefits of anticoagulationCornerstone of treatmentProspective cohort studyRecurrent pregnancy lossAdequate clinical trialsV Leiden mutationAcquired ThrombophiliaAntiplatelet therapyCohort studyPregnancy lossThrombophilic mutationsClinical trialsLeiden mutationNatural anticoagulantsRoutine useThrombophiliaGene mutationsAnticoagulationComplications
2010
Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer
Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, Edge S, Shapiro CL, Dressler L, Paskett E, Kimmick G, Orcutt J, Scalzo A, Winer E, Levine E, Shahab N, Berliner N, B F. Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer. Journal Of The National Cancer Institute 2010, 102: 942-949. PMID: 20554945, PMCID: PMC2897879, DOI: 10.1093/jnci/djq211.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Agents, HormonalBreast NeoplasmsCase-Control StudiesChemotherapy, AdjuvantEstrogen Receptor ModulatorsFactor VFemaleHumansLogistic ModelsMiddle AgedMultivariate AnalysisMutationOdds RatioPrevalenceRisk FactorsSelective Estrogen Receptor ModulatorsSmokingTamoxifenThromboembolismConceptsFactor V LeidenEarly-stage breast cancerThromboembolic eventsAdjuvant tamoxifenFVL mutationBreast cancerTamoxifen useTE riskControl subjectsOdds ratioFactor V Leiden mutationCase-control studyConditional logistic regressionV Leiden mutationPostmenopausal womenThromboembolism riskThrombosis riskMultivariable modelTherapeutic decisionsV LeidenLeiden mutationHigh riskPositive testTamoxifenCancer
1998
Stroke in a Neonate Heterozygous for Factor V Leiden
Varelas P, Sleight B, Rinder H, Sze G, Ment L. Stroke in a Neonate Heterozygous for Factor V Leiden. Pediatric Neurology 1998, 18: 262-264. PMID: 9568926, DOI: 10.1016/s0887-8994(97)00166-5.Peer-Reviewed Original Research
1997
Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers
Grossman D, Heald P, Wang C, Rinder H. Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers. Journal Of The American Academy Of Dermatology 1997, 37: 409-413. DOI: 10.1016/s0190-9622(18)30738-2.Peer-Reviewed Original ResearchVenous leg ulcersFactor V Leiden mutationV Leiden mutationFactor V LeidenAnticardiolipin antibodiesLeg ulcersLeiden mutationV LeidenVenous leg ulcerationCommon risk factorsPartial thromboplastin timeAPC resistanceEnzyme-linked immunosorbentProtein C resistanceConsecutive patientsLeg ulcerationVenous thrombosisRisk factorsSkin ulcerationThromboplastin timeGeneral populationPatientsUlcersMethods TwentyLow APC ratioActivated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers
Grossman D, Heald P, Wang C, Rinder H. Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers. Journal Of The American Academy Of Dermatology 1997, 37: 409-413. PMID: 9308555, DOI: 10.1016/s0190-9622(97)70141-5.Peer-Reviewed Original ResearchConceptsVenous leg ulcersFactor V Leiden mutationV Leiden mutationFactor V LeidenAnticardiolipin antibodiesLeg ulcersLeiden mutationV LeidenVenous leg ulcerationCommon risk factorsPartial thromboplastin timeAPC resistanceEnzyme-linked immunosorbentProtein C resistanceConsecutive patientsHypercoagulable stateLeg ulcerationVenous thrombosisRisk factorsSkin ulcerationThromboplastin timeGeneral populationPatientsUlcersLow APC ratio
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply